Augmenix, Inc. Closes $6.1 Million Financing

WALTHAM, Mass., Oct. 16 /PRNewswire/ -- Augmenix announced today that it has
closed a $6.1 million Series B financing. The round was led by Ascension
Health Ventures (AHV) in St. Louis, Mo., with continued participation by
existing investors, Versant Ventures and Pinnacle Ventures. Also
participating were Catalyst Health Ventures and several private investors.

"The field of radiation oncology has traditionally been of a large capital
equipment mindset in solving problems. Augmenix plans to bring novel
biomaterials technology into this field to create absorbable devices that will
have a huge impact on how clinicians are able to improve targeting of
radiotherapy while minimizing radiation damage to organs at risk," commented
Amar Sawhney, Augmenix President and CEO.

The proceeds will be used to conduct the clinical and commercial development
of the SpaceOAR((TM)). System in Europe and the United States, as well as to
develop other products in the Augmenix pipeline.

"We are excited about working with Augmenix to meet significant medical needs
in radiation oncology and urology. We have worked with Amar and his team
before and like the technology, as well as the rapid and cost-effective
execution model embraced by Augmenix," said Tara Butler, Investment Director,
AHV, who will join the company's Board of Directors.

About Augmenix, Inc.:
Augmenix, Inc. is a privately held company based in Waltham, Mass., focused on
the development and commercialization of implantable biomaterial based
solutions for improved radiotherapy safety and/or efficacy. Augmenix's first
product, SpaceOAR system is an injectable tissue spacer that will decrease
rectal morbidity or enable improved efficacy in prostate radiotherapy. The
company was founded in 2008.

About Ascension Health Ventures:
Ascension Health Ventures (www.ascensionhealthventures.org) was launched in
2001 as a wholly-owned subsidiary of Ascension Health. AHV's role has been to
construct and manage a strategic portfolio of investments that deliver a
venture investment return, have the potential to transform the healthcare
industry and significantly enhance the quality of patient care. CHV II, LP, a
limited partnership between Ascension Health, Catholic Health Initiatives,
Catholic Health East and Catholic Healthcare West, has been formed to expand
this strategic investment initiative to other Catholic healthcare systems. AHV
is the general partner of CHV II, LP.

SOURCE Augmenix, Inc.

Bradley Poff, General Manager of Augmenix, Inc., bpoff@augmenix.com